---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091802"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:29:00.016179+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q2 net loss $0.69/sh; cash $688M; new preclinical programs unveiled

## Summary
- Q2 net loss $92.2M ($0.69/share) vs $98.5M ($0.81) in Q2 2023.
- Cash, equivalents & investments $688.4M; expected to fund operations into H2 2026.
- Announced 3 new preclinical programs: vascular malformations (PI3Kα), Fabry disease (non-inhibitory chaperone), NRAS-selective inhibitor.
- Initiated Pfizer collaboration for RLY-2608 + fulvestrant + atirmociclib triplet; clinical start by end of 2024.
- RLY-2608+fulvestrant doublet data update in Q4 2024 with ~100 patients safety database and ~60 at 600mg BID.

## SEC filing metadata
- accession: 0000950170-24-091802
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017024091802/0000950170-24-091802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017024091802/rlay-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091802
- JSON: https://secwatch.observer/filing/0000950170-24-091802.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.